Shenzhen Bioeasy Biotechnology Co. Ltd.

Yirui Bio released its 2026 interim report. First-half revenue was 128 million yuan, up 17.5% year on year, but the company posted a loss of 19.73 million yuan, down 943.2% year on year. Net profit attributable to the parent after deducting non-recurring items widened from a loss of 2.06 million yuan in the same period last year to a loss of 23.54 million yuan. Net operating cash flow was negative 5.87 million yuan, down 28,750.3% year on year, and earnings per share were negative 0.0487 yuan. In the second quarter, revenue was 70.72 million yuan, up 18.0% year on year, while net profit attributable to the parent was a loss of 9.47 million yuan, down 266.5% year on year. As of the end of the second quarter, total assets were 1.48 billion yuan, down 2.9% from the end of the previous year, and net assets attributable to the parent were 874 million yuan, down 3.3%. The company's business is mainly concentrated in two areas: rapid food safety testing and animal diagnostics. Rapid food safety testing revenue reached 110 million yuan, up 4.86% year on year, while animal diagnostics revenue was 9.03 million yuan, a significant increase. The company said it is actively expanding in international markets, particularly in dairy testing, mycotoxins, and pesticide residues, to enhance the international influence of its brand.